Robert Kralovics

Robert Kralovics

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Robert Kralovics

Department of Laboratory Medicine Medical University of Vienna Vienna Austria

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RKRobert Kralovics
Robert Kralovics
FPFabrizio Passamonti
Fabrizio Passamonti
ABAndreas S. Buser
Andreas S. Buser
STSoon-Siong Teo
Soon-Siong Teo
RTRalph Tiedt
Ralph Tiedt
RSRadek C. Skoda
Radek C. Skoda
Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases. We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis). Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene. In patients with 9pLOH, JAK2 had a homozygous G→T transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F). All 51 patients with 9pLOH had the V617F mutation. Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation. The frequency of V617F was 65 percent among patients with polycythemia vera (83 of 128), 57 percent among patients with idiopathic myelofibrosis (13 of 23), and 23 percent among patients with essential thrombocythemia (21 of 93). V617F is a somatic mutation present in hematopoietic cells. Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F. Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages. Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2. A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.

19 December 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TKThorsten Klampfl
Thorsten Klampfl
HGHeinz Gisslinger
Heinz Gisslinger
AHAshot S. Harutyunyan
Ashot S. Harutyunyan
HNHarini Nivarthi
Harini Nivarthi
ERElisa Rumi
Elisa Rumi
RKRobert Kralovics
Robert Kralovics
Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients.

1 July 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
AZAlexander Zimprich
Alexander Zimprich
ABAnna Benet-Pagès
Anna Benet-Pagès
WSWalter Struhal
Walter Struhal
EGElisabeth Graf
Elisabeth Graf
SESebastian H. Eck
Sebastian H. Eck
TSTim M. Strom
Tim M. Strom

9 February 2017 in Blood
Verified
Journal Article
Closed access
PDF file
WVWilliam Vainchenker
William Vainchenker
RKRobert Kralovics
Robert Kralovics
The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin (CALR), and myeloproliferative leukemia virus (MPL), abnormally activate the cytokine receptor/JAK2 pathway and their downstream effectors, more particularly the STATs. The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MPL mutants are restricted to MPL activation. This explains why JAK2V617F is associated with polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whereas CALR and MPL mutants are found in ET and PMF. Other mutations in genes involved in epigenetic regulation, splicing, and signaling cooperate with the 3 MPN drivers and play a key role in the PMF pathogenesis. Mutations in epigenetic regulators TET2 and DNMT3A are involved in disease initiation and may precede the acquisition of JAK2V617F. Other mutations in epigenetic regulators such as EZH2 and ASXL1 also play a role in disease initiation and disease progression. Mutations in the splicing machinery are predominantly found in PMF and are implicated in the development of anemia or pancytopenia. Both heterogeneity of classical MPNs and prognosis are determined by a specific genomic landscape, that is, type of MPN driver mutations, association with other mutations, and their order of acquisition. However, factors other than somatic mutations play an important role in disease initiation as well as disease progression such as germ line predisposition, inflammation, and aging. Delineation of these environmental factors will be important to better understand the precise pathogenesis of MPN.

3 April 2014 in Blood
Verified
Journal Article
Closed access
PDF file
PLPontus Lundberg
Pontus Lundberg
AKAxel Karow
Axel Karow
RNRonny Nienhold
Ronny Nienhold
RLRenate Looser
Renate Looser
HHHui Hao-Shen
Hui Hao-Shen
RSRadek C. Skoda
Radek C. Skoda
Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by aberrant hematopoietic proliferation and an increased tendency toward leukemic transformation. We used targeted next-generation sequencing (NGS) of 104 genes to detect somatic mutations in a cohort of 197 MPN patients and followed clonal evolution and the impact on clinical outcome. Mutations in calreticulin (CALR) were detected using a sensitive allele-specific polymerase chain reaction. We observed somatic mutations in 90% of patients, and 37% carried somatic mutations other than JAK2 V617F and CALR. The presence of 2 or more somatic mutations significantly reduced overall survival and increased the risk of transformation into acute myeloid leukemia. In particular, somatic mutations with loss of heterozygosity in TP53 were strongly associated with leukemic transformation. We used NGS to follow and quantitate somatic mutations in serial samples from MPN patients. Surprisingly, the number of mutations between early and late patient samples did not significantly change, and during a total follow-up of 133 patient years, only 2 new mutations appeared, suggesting that the mutation rate in MPN is rather low. Our data show that comprehensive mutational screening at diagnosis and during follow-up has considerable potential to identify patients at high risk of disease progression. Key Points The total number of somatic mutations was inversely correlated with survival and risk of leukemic transformation in MPN. The great majority of somatic mutations were already present at MPN diagnosis, and very few new mutations were detected during follow-up.

6 March 2014 in Blood
Verified
Journal Article
Open access
PDF file
ERElisa Rumi
Elisa Rumi
DPDaniela Pietra
Daniela Pietra
VFVirginia Valeria Ferretti
Virginia Valeria Ferretti
TKThorsten Klampfl
Thorsten Klampfl
AHAshot S. Harutyunyan
Ashot S. Harutyunyan
MCMario Cazzola
Mario Cazzola
Key Points: JAK2 (V617F)-mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm. CALR-mutated essential thrombocythemia is a distinct disease entity not only at the molecular level, but also with respect to clinical outcomes.